¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"luteal phase deficiency"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • intuitive phase
    Á÷°ü±â
  • involutional phase
    ÅðÈ­±â
  • isovolumic contraction phase
    µî¿ëÀû¼öÃà±â
  • implantational phase
    Âø»ó±â
  • inflow phase
    À¯ÀÔ±â
  • in-phase image
    À§»ó³»¿µ»ó
  • inspiratory phase
    µé¼û»ó, Èí±â»ó
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • internal phase
    ºÐ»ê±â
  • latent phase
    1. ÀáÀç±â 2. Àẹ±â
  • leptotene phase
    °¡´Â¼¶À¯±â, ¼¼»ç±â
  • logarithmic phase
    ´ë¼öÁõ½Ä±â
  • lactiferous phase
    ¼öÀ¯±â
  • lysogenic phase
    ¿ë¿ø±â
  • mitosis phase
    À¯»çºÐ¿­±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • circadian-phase intervention
    ÀÏÁÖ±âÀ§»óÁßÀç
  • colostral phase
    ùÁ¥±â, ÃÊÀ¯±â
  • compression phase
    ¾ÐÃà»ó
  • phase coherence
    À§»ó°áÁý
  • phase constant
    À§»ó»ó¼ö
  • phase contrast
    À§»ó´ëÁ¶
  • phase curve
    À§»ó°î¼±
  • death phase
    »ç¸ê±â
  • delayed sleep phase
    Áö¿¬¼ö¸éÀ§»ó
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • depressive phase
    ¿ì¿ï»ó
  • diastolic phase
    È®Àå±â, À̿ϱâ
  • diplotene phase
    °ã¼¶À¯±â
  • diurnal phase
    ÁÖ°£»ó
  • phase delay
    À§»óÁö¿¬
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • iga deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ
  • immune deficiency disease
    ¸é¿ª°áÇÌÁúȯ<º´>.
  • immunoglobulin A deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ(Áõ)
  • immunologic deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunologic deficiency syndrome
    ¸é¿ª°áÇÌ ÁõÈıº(¡­ÌÀù¹ ñøý¦ÏØ)
  • immunological deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • inosine phosphorylase deficiency
    À̳ë½ÅÆ÷½ºÆ÷¸±¶óÁ¦°áÇÌ(Áõ)
  • phosphate dehydrogenase deficiency
    Àλ꿰ݼö¼ÒÈ¿¼Ò°áÇÌÁõ
  • pituitary deficiency
    ÇϼöüºÎÀü(¡­ÝÕîï).
  • pituitary deficiency
    üºÎÀü(ù»á÷ô÷ÝÕîï)
  • pituitary hormone deficiency (pituitary dwarfism)
    ³úÇϼöüȣ¸£¸ó°áÇÌ (³úÇϼöü³­
  • protein-calorie deficiency
    ´Ü¹é(Áú)¿­·®°áÇÌ(Ó±ÛÜ(òõ)æðÕáÌÀù¹)
  • pyridoxine deficiency
    ÇǸ®µ¶½Å°áÇÌ(Áõ)(¡­ÌÀù¹(ñø))
  • reaction deficiency
    ¹ÝÀÀ°áÇÌ
  • 3D phase contrast angiography
    3Â÷¿ø À§»ó ´ëÁ¶ Ç÷°üÁ¶¿µ¼ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • cobalamin deficiency
    Äڹ߶ó¹Î°áÇÌ
  • color vision deficiency
    »ö°¢ÀÌ»ó
  • combined immunity deficiency syndrome
    º¹Çո鿪°áÇÌÁõÈıº.
  • combined immunity deficiency synsdrome
    º¹Çո鿪°áÇÌÁõÈıº.
  • complement deficiency
    º¸Ã¼°áÇÌ
  • congenital deficiency of glucuronyl transfe ra se
    ¼±Ãµ¼º ±Û·çÄí·Ð»ê Àü À§È¿¼Ò°áÇÌÁõ(¡­ï®êÈý£áÈÌÀù¹ñø).
  • copper deficiency
    ±¸¸®°áÇÌÁõ(¡­ÌÀù¹ñø)
  • cytochrome C oxidase deficiency
    ½ÃƮũ·Ò C ¿Á½Ã´ÙÁ¦(»êÈ­È¿¼Ò)°áÇÌ
  • cytochrome b5 reductase deficiency
    ½ÃÅäÅ©·Ò b5 ȯ¿øÈ¿¼Ò °áÇÌ
  • cytogenetic deficiency
    ¼¼Æ÷¹ß»ý°áÇÌ
  • deficiency
    °áÇÌ(Áõ)(ÌÀù¹ñø)
  • deficiency
    °áÇÌ
  • deficiency (monstrous tumor)
    °áÇÌ (±«¹°Á¾)
  • deficiency (nanismus)
    °áÇÌ(³­ÀåÀÌÁõ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Proleptotene phase
    Dz¼¶À¯±â
    [¿¾ ¿ë¾î] Àü¼¼»ç±â
  • S phase
    ÇÕ¼º±â [S±â]
    [¿¾ ¿ë¾î] ÇÕ¼º±â
  • G1 phase
    ÇÕ¼ºÀü±â [G1±â]
    [¿¾ ¿ë¾î] ÀÏÂ÷ÈÞÁö±â
  • G2 phase
    ÇÕ¼ºÈıâ [G2±â]
    [¿¾ ¿ë¾î] ÀÌÂ÷ÈÞÁö±â
  • Ischemic phase
    ÇãÇ÷±â
    [¿¾ ¿ë¾î] ºóÇ÷±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • stationary phase
    "Á¤Áö»ó(ïÎò­ßÓ), Á¤Áö±â(ïÎò­Ñ¢)"
  • transient phase
    °úµµ»ó(ΦԤßÒ)
  • vapor phase chromatography
    Áõ±â»ó(ñúѨßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • respiratory ordered phase encoding
    È£Èí¼øÀ§»óºÎȣȭ
  • resting phase
    È޽ıâ
  • spin phase
    ½ºÇÉÀ§»ó
  • spin phase effect
    ½ºÇÉÀ§»óÈ¿°ú
  • test phase
    ½ÃÇè±â
  • venous phase
    Á¤¸Æ»ó, Á¤¸Æ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ARP absolute refractory period; American Registry of Pathologists; anticipated recovery path; apolipopro...
ASPS advanced sleep phase syndrome
CPIR cephalic-phase insulin release
CYCLOPS cyclically ordered phase sequence
DSP decreased sensory perception; delayed sleep phase; desmoplakin; dibasic sodium phosphate; digital si...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AIDS Acquired Immune Deficiency Disease Syndrome
alpha1ATD Alpha-1-antitrypsin deficiency
AATD Alpha1-antitrypsin deficiency
BLAD Bovine Leukocyte Adhesion Deficiency
CPHD Combined pituitary hormone deficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • vitamin I deficiency
    ºñŸ¹Î °áÇÌ, ºñŸ¹Î °áÇÌÁõ
  • vitamin K deficiency
    ºñŸ¹Î K °áÇÌ, ºñŸ¹Î K °áÇÌÁõ
    Ç÷¾×ÀÇ ÀÀ°í ½Ã°£ÀÌ ±æ¾îÁø´Ù.
  • accelerated death phase
    °¡¼Ó »ç¸ê±â
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
    ¹Ì»ý¹° ¹è¾ç ½Ã °©Àڱ⠼ºÀåÀÌ Áõ°¡ÇÏ´Â ½Ã±â.
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute phase serum
    ±Þ¼º º´±â Ç÷û
  • anal-sadistic phase
    Ç×¹®-°¡Çбâ, Ç×¹®-°¡ÇÐ ½Ã±â
  • arousal phase
    ÀáÀ» ±ú´Â ½Ã±â
  • arterial phase
    µ¿¸Æ ±â
  • bacterial phase
    ¼¼±Õ »ó
    ¼¼±ÕÀÌ ´«¿¡ º¸ÀÌ´Â ¾ç»ó.
  • closing phase
    Æó±¸ ´Ü°è
  • dispersed phase
    ºÐ»ê »ó
  • equilibrium phase diagram
    ÆòÇü »óŵµ
    ÇÕ±ÝÀÇ Á¶¼º°ú ¿Âµµ°¡ ¹Ù²î¾îÁ³À» ¶§ÀÇ ÆòÇü »óÅ¿¡¼­ÀÇ »óÀÇ º¯È­¸¦ º¸ÀÎ ±×¸².
  • expiratory phase
    È£±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
phase separation <chemistry> The separation of fluid phases that contain different concentrations of common components.
Occurs with partially miscible solvents used in many biochemical separation methods. Also temperature dependent phase separation occurs with some detergent solutions. With reference to membranes means the segregation of lipid components into domains that have different chemical composition.
(31 Dec 1997)
phase shift <microscopy> A change in the phase relationship between two alternating quantities of the same frequency.
(05 Aug 1998)
phase variation <microbiology> Alteration in the expression of surface antigens by bacteria.
For example: Salmonella can express either of two forms of flagellin, H1 and H2, that are coded by different genes. Control of which form is expressed is brought about by inversion of the promoter for the H2 gene, which if functional (noninverted) is associated with the expression of H2 and the production of a repressor of the H1 gene.
Inversion occurs about every 1000 bacterial divisions and is under the control of another gene, hin, that is within the invertable sequence.
(31 Dec 1997)
chronic phase Refers to the early stages of chronic myelogenous leukaemia. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.
(12 Dec 1998)
microscopy, phase-contrast A form of interference microscopy in which variations of the refracting index in the object are converted into variations of intensity in the image. This is achieved by the action of a phase plate.
(12 Dec 1998)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
M phase Mitotic phase of cell cycle of eukaryotic cells, as distinct from the remainder, which is known as interphase (and that can be further subdivided as G1, s and G2). Beginning of M is signalled by separation of centrioles, where present and by the condensation of chromatin into chromosomes. M phase ends with the establishment of nuclear membranes around the two daughter nuclei, normally followed immediately by cell division (cytokinesis).
(18 Nov 1997)
M phase promoting factor Protein whose levels rise rapidly just before and fall away just after, mitosis. Thought to be a trigger for mitosis.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á